Herophilus is a San Francisco based neurotherapeutics development company that employs AI-driven phenotypic screening to discover and develop novel drugs for complex brain diseases, disorders for which traditional discovery techniques have proved least successful. Herophilus industrializes the recent revolution in complex in vitro experimental science, leveraging robotic automation and machine learning, to characterize the etiology and expression of disease at molecular, cellular, and tissue levels. These "deep phenotypes" are exploited to identify novel therapeutic targets and drug treatments.